Neo-Endusix (Tenoxicam)

Tenoxicam blocks cyclooxygenase enzymes (COX‑1 and COX‑2), which reduces the production of prostaglandins—key mediators of inflammation, pain and fever—thereby providing anti‑inflammatory and analgesic effects.

The prescribed dose of Neo-Endusix is determined by the treating physician based on the patient’s condition, severity, and clinical response. Dosing regimens are individualized and should follow the prescriber’s instructions.

Safety data for Tenoxicam in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the Neo-Endusix product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and necessary import documentation.

Tenoxicam belongs to the oxicam class, offering a longer half‑life than many traditional NSAIDs, which may allow less frequent dosing. Its efficacy in reducing inflammation is comparable to other potent NSAIDs, but individual tolerability and safety profiles can differ.

Neo-Endusix should be stored at ambient temperature, below 25 °C, in its original packaging, protected from moisture and direct light to maintain stability.

Neo-Endusix is supplied as a sterile injection and can be given either intramuscularly or intravenously by a qualified healthcare professional, following aseptic technique and appropriate dosing guidelines.

Serious risks include severe skin reactions such as Stevens‑Johnson syndrome, significant hepatic injury, anaphylaxis, blood dyscrasias, and increased risk of cardiovascular thrombotic events. Immediate medical attention is required if any of these occur.

Neo-Endusix should be avoided in patients with known hypersensitivity to Tenoxicam or other oxicams, in those with severe renal or hepatic impairment, and in individuals with active gastrointestinal ulceration or bleeding disorders unless specifically directed by a physician.